| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $1,671,019 ) |
| | 2022 | 2022 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44CA268541 | IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 1 | NIH | 5/31/2022 | $1,371,030 |
| | 2022 | 2022 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43AI165096 | Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis | 000 | 1 | NIH | 4/21/2022 | $299,989 |
| | 2022 | 2019 | VIVREON BIOSCIENCES LLC | 4940 CARROLL CANYON RD | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43AG061995 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 1 | NIH | 2/22/2022 | $0 |
| | 2022 | 2019 | VIVREON BIOSCIENCES LLC | 4940 CARROLL CANYON RD | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 2 | NIH | 12/21/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $500,431 ) |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 5 | NIH | 2/17/2021 | $193,392 |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 001 | 5 | NIH | 3/11/2021 | -$193,392 |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 001 | 5 | NIH | 3/11/2021 | $193,392 |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 003 | 5 | NIH | 6/30/2021 | $0 |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43DA053010 | Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | 001 | 1 | NIH | 4/19/2021 | $55,000 |
| | 2021 | 2021 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43AR079968 | Predevelopment of VV8321, a Novel CRAC Channel Therapeutic for the Treatment of Osteoarthritis | 000 | 1 | NIH | 9/23/2021 | $252,039 |
| | 2021 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 002 | 5 | NIH | 6/30/2021 | $0 |
| | 2021 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43DA053010 | Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | 000 | 1 | NIH | 3/24/2021 | $0 |
| | 2021 | 2019 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 2 | NIH | 2/19/2021 | $0 |
| | 2021 | 2019 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43AG061995 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 1 | NIH | 1/27/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,074,472 ) |
| | 2020 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 5 | NIH | 5/20/2020 | $1,249,999 |
| | 2020 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 2 | NIH | 4/29/2020 | $224,700 |
| | 2020 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R44CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 001 | 2 | NIH | 8/21/2020 | $249,806 |
| | 2020 | 2020 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43DA053010 | Investigation of Microglial CRAC Channels as a Novel Drug Target for Opioid Use Disorder | 000 | 1 | NIH | 9/22/2020 | $349,967 |
|
| Issue Date FY: 2019 ( Subtotal = $2,525,180 ) |
| | 2019 | 2019 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R43AG061995 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 1 | NIH | 7/26/2019 | $270,902 |
| | 2019 | 2019 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R44CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 2 | NIH | 8/27/2019 | $1,004,278 |
| | 2019 | 2019 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 4 | NIH | 6/6/2019 | $1,250,000 |
| | 2019 | 2018 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 1 | NIH | 6/20/2019 | $0 |
| | 2019 | 2017 | VIVREON BIOSCIENCES, LLC | 4940 CARROLL CANYON RD STE 110 | SAN DIEGO | CA | 92121-1735 | SAN DIEGO | USA | R43AI134205 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis | 000 | 1 | NIH | 1/8/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $970,976 ) |
| | 2018 | 2018 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 001 | 3 | NIH | 6/11/2018 | $745,976 |
| | 2018 | 2018 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R43CA224454 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy | 000 | 1 | NIH | 3/2/2018 | $225,000 |
| | 2018 | 2016 | VIVREON BIOSCIENCES, LLC | 7558 TRADE STREET | SAN DIEGO | CA | 92121-2412 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 1 | NIH | 10/23/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $966,300 ) |
| | 2017 | 2017 | VIVREON BIOSCIENCES, LLC | 6990 CARROLL RD STE A | SAN DIEGO | CA | 92121-3285 | SAN DIEGO | USA | R43AI134205 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, for the Treatment of Ulcerative Colitis | 000 | 1 | NIH | 6/23/2017 | $219,975 |
| | 2017 | 2017 | VIVREON BIOSCIENCES, LLC | 6990 CARROLL RD STE A | SAN DIEGO | CA | 92121-3285 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 2 | NIH | 7/24/2017 | $746,325 |
|
| Issue Date FY: 2016 ( Subtotal = $222,453 ) |
| | 2016 | 2016 | VIVREON BIOSCIENCES, LLC | 6990 CARROLL RD STE A | SAN DIEGO | CA | 92121-3285 | SAN DIEGO | USA | R44AG055205 | Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease | 000 | 1 | NIH | 9/15/2016 | $222,453 |
|
|
